Dr. Reddy's Laboratories Ltd
corporate_fare Company Profile
Dr. Reddy's Laboratories Ltd (NYSE:RDY) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 38 items for RDY at importance 7 or higher on its 1–10 market-impact scale.
Recent high-impact activity:
- Dr. Reddy's Launches First Generic Semaglutide Injection in Canada
- Dr. Reddy's Reports Q4 & FY26 Results, Highlights Semaglutide Approvals & Strong Growth in Key Markets
- Dr. Reddy's Reports Sharp Q4 Profit Decline Amidst One-Off Charges; Full-Year Profit Down 24%
- Dr. Reddy's Strengthens Board with AI Expert, Elevates Key India Generics Head
- Dr. Reddy's Secures Health Canada Approval for First Generic Semaglutide Injection
Financial Snapshot
Insider Transactions
RDY files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.